Melatonin Ligands for Selective MT1 and MT2 Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current melatonin-based treatments for depression and sleep disorders have limitations in efficacy and specificity, particularly in targeting MT1 and MT2 receptor subtypes, and there is a need for novel melatonin ligands with improved antidepressant and sleep-inducing properties.
Innovation Solution
Development of novel melatonin ligands, specifically compounds like N-[2-(diphenylamino)ethyl]acetamide and its derivatives, which exhibit high binding affinity for MT1 and MT2 melatonin receptors, offering antidepressant and sleep-inducing effects through interaction with these receptor subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If melatonin-based treatments are used for depression and sleep disorders, then sleep-inducing effects are achieved, but antidepressant efficacy and receptor subtype specificity are insufficient
Solution Approach 1:
The patent segments the melatonin receptor system into distinct subtypes (MT1 and MT2) and develops ligands with selective affinity for each subtype. This segmentation allows the treatment to target specific physiological pathways - MT1 for sleep regulation and MT2 for circadian rhythm and antidepressant effects - thereby improving both antidepressant efficacy and receptor subtype specificity simultaneously
Solution Approach 2:
The patent applies local quality by designing ligands with differentiated binding properties for different receptor subtypes. Specific chemical modifications at particular positions on the ligand molecule create localized interactions that enhance selectivity for MT1 or MT2 receptors, enabling tailored therapeutic effects for different clinical conditions
2Reliability
If existing melatonin ligands are used, then some therapeutic effects are achieved, but binding affinity and therapeutic effectiveness are limited
Solution Approach 1:
The patent systematically changes chemical parameters of the melatonin ligand structure, including substituent types, positions, and stereochemistry. These parameter changes optimize the ligand-receptor interaction, significantly enhancing binding affinity (lower Ki values) and improving therapeutic effectiveness for both depression and sleep disorders
Solution Approach 2:
The patent creates composite molecular structures by combining melatonin's core structure with additional functional groups and moieties. These composite ligands integrate multiple pharmacophoric elements that work synergistically to enhance binding affinity and therapeutic effectiveness beyond what natural melatonin alone can achieve
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These novel melatonin ligands demonstrate significant antidepressant activity, reducing immobility in forced swim tests, increasing anxiety-like behavior measures, and promoting sleep patterns, showcasing improved efficacy compared to existing melatonin-based treatments.
Implementation Method 1
Most of the physiological effects of MLT result from the activation of high-affinity G-protein coupled receptors, two of which (MT1 and MT2) have been found in mammals including humans
Implementation Method 2
activation of high-affinity G-protein coupled receptors, two of which (MT1 and MT2) have been found in mammals including humans
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Novel melatonin ligands of Formula (I) or pharmaceutically acceptable salts thereof wherein: n is 1 or 2; m is 0, 1 or 2; p is 0, 1 , 2, 3, 4, 5, 6, 7 or 8; v is 2 or 3; A is aryl or heteroaryl; Z is O, S or NR8;Y is selected from the group consisting of hydrogen, aryl, heteroaryl, CrC6 alkyl, C3-C6 cycloalkyl, and R is selected from the group consisting of hydrogen, hydroxyl, -OCF3, CF3, C1-C8 alkyl, C1C8 alkyloxy, C1C8 alkylthio, halogen and -Z-(CH2)P-A; R1 is selected from the group consisting of C1C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1C4 alkyl, hydroxy-substituted C3-C6 cycloalkyl, and NHR5, wherein R5 is C1C3 alkyl or C3-C6 cycloalkyl; R2 is selected from the group consisting of: hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R3 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R and R3 may be connected together to form an -0-(CH2)v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system; R4 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen; R6 is selected from the group consisting of hydrogen and C1C6 alkyl; R7 is selected from the group consisting of hydrogen, C1C4 alkyl, C1C4alkyloxy, OCF3, CF3, hydroxyl, and halogen; and R8 is selected from the group consisting of hydrogen and C1C4 alkyl.